Literature DB >> 19490036

Pregnancy, delivery, and outcome for the child in maternal epilepsy.

Gyri Veiby1, Anne K Daltveit, Bernt A Engelsen, Nils E Gilhus.   

Abstract

PURPOSE: To investigate pregnancy, delivery, and child outcome in an unselected population of women with both treated and untreated epilepsy.
METHODS: In the compulsory Medical Birth Registry of Norway, all 2,861 deliveries by women with epilepsy recorded from 1999-2005 were compared to all 369,267 nonepilepsy deliveries in the same period.
RESULTS: The majority (66%, n = 1900) in the epilepsy group did not use antiepileptic drugs (AEDs) during pregnancy. A total of 961 epilepsy-pregnancies were exposed to AEDs. Compared to nonepilepsy controls, AED-exposed infants were more often preterm (p = 0.01), and more often had birth weight <2,500 g (p < 0.001), head circumference <2.5 percentile (p < 0.001), and low Apgar score (p = 0.03). Small-for-gestational-age (SGA) infants (<10 percentile) occurred more frequently in both AED-exposed (p = 0.05) and unexposed (p = 0.02) epilepsy-pregnancies. Frequency of major congenital malformations (MCMs) was 2.8% (n = 81) in the epilepsy group versus 2.5% in controls (p = 0.3). Increased risk for MCMs could be demonstrated only for exposure to valproate (5.6%, p = 0.005) and AED polytherapy (6.1%, p = 0.02). Neonatal spina bifida was not significantly increased, but was a major indication for elective pregnancy termination among women with epilepsy. Cesarean section was performed more often in maternal epilepsy, regardless of AED-exposure (p < 0.001). DISCUSSION: Adverse pregnancy and birth outcome in women with epilepsy is mainly confined to AED-exposed pregnancies, although some risks are associated also with untreated epilepsy. The risk for congenital malformations was lower than previously reported. This could be due to a shift in AED selection, folic acid supplement, or possibly reflect the true risks in an unselected epilepsy population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19490036     DOI: 10.1111/j.1528-1167.2009.02147.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  26 in total

1.  The use of central nervous system active drugs during pregnancy.

Authors:  Bengt Källén; Natalia Borg; Margareta Reis
Journal:  Pharmaceuticals (Basel)       Date:  2013-10-10

Review 2.  Treatment of Juvenile Myoclonic Epilepsy in Patients of Child-Bearing Potential.

Authors:  Anna Serafini; Elizabeth Gerard; Pierre Genton; Arielle Crespel; Philippe Gelisse
Journal:  CNS Drugs       Date:  2019-03       Impact factor: 5.749

3.  Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy.

Authors:  Gyri Veiby; Anne Kjersti Daltveit; Bernt A Engelsen; Nils Erik Gilhus
Journal:  J Neurol       Date:  2014-01-22       Impact factor: 4.849

Review 4.  Advances in Epidemiological Methods and Utilisation of Large Databases: A Methodological Review of Observational Studies on Central Nervous System Drug Use in Pregnancy and Central Nervous System Outcomes in Children.

Authors:  Zixuan Wang; Phoebe W H Ho; Michael T H Choy; Ian C K Wong; Ruth Brauer; Kenneth K C Man
Journal:  Drug Saf       Date:  2019-04       Impact factor: 5.606

5.  Making the best use of data not created for research.

Authors:  Kristin Palmsten; Christina D Chambers
Journal:  Paediatr Perinat Epidemiol       Date:  2018-03-25       Impact factor: 3.980

6.  Mortality and Morbidity During Delivery Hospitalization Among Pregnant Women With Epilepsy in the United States.

Authors:  Sarah C MacDonald; Brian T Bateman; Thomas F McElrath; Sonia Hernández-Díaz
Journal:  JAMA Neurol       Date:  2015-09       Impact factor: 18.302

7.  Effects of maternal epilepsy and antiepileptic drug use during pregnancy on perinatal health in offspring: nationwide, retrospective cohort study in Finland.

Authors:  Miia Artama; Mika Gissler; Heli Malm; Annukka Ritvanen
Journal:  Drug Saf       Date:  2013-05       Impact factor: 5.606

8.  Differential effects of antiepileptic drugs on neonatal outcomes.

Authors:  P B Pennell; A M Klein; N Browning; G A Baker; J Clayton-Smith; L A Kalayjian; J D Liporace; M Privitera; T Crawford; D W Loring; K J Meador
Journal:  Epilepsy Behav       Date:  2012-06-29       Impact factor: 2.937

Review 9.  Antiepileptic drugs in women with epilepsy during pregnancy.

Authors:  Evan Gedzelman; Kimford J Meador
Journal:  Ther Adv Drug Saf       Date:  2012-04

10.  Exposure to antiepileptic drugs in utero and child development: a prospective population-based study.

Authors:  Gyri Veiby; Anne K Daltveit; Synnve Schjølberg; Camilla Stoltenberg; Anne-Siri Øyen; Stein E Vollset; Bernt A Engelsen; Nils E Gilhus
Journal:  Epilepsia       Date:  2013-07-19       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.